Breast Cancer Stats
We're here to change the stats. Our mission: zero deaths from breast cancer by 2030.
You have returned to the top of the page.
Breast cancer is the most commonly diagnosed cancer in Australia.
Its incidence is increasing – with 1 in 7 Australian women and 1 in 675 Australian men expected to be diagnosed in their lifetime.
The disease develops when cells within the breast grow abnormally and multiply to form a tumour. Thanks to medical research, breast cancer that is contained within the breast is now largely treatable. Since the National Breast Cancer Foundation (NBCF) started funding research in 1994, five-year breast cancer survival rates have improved from 76% to 91%.
It’s progress to be proud of. But the job’s not done. 8 Australian women still lose their life to the disease every single day.
In Australia, the overall five-year survival rate for breast cancer in females is 91%. If the cancer is limited to the breast, 96% of patients will be alive five years after diagnosis; this figure excludes those who die from other diseases. If the cancer has spread to the regional lymph nodes, five-year relative survival drops to 80%.
Targeted, world-class research is the only way to stop women and men dying from breast cancer. By gaining a better understanding of how breast cancer tumours originate, grow and spread, we can save more lives.
NBCF is committed to funding research to reach one determined goal: zero deaths from breast cancer by 2030.
There are a range of factors that contribute to your chance of developing breast cancer. Some risks can be reduced, while others you might have no control over.
Breast cancer is a complex disease, made up of many different subtypes. Learn more about the stages and types of breast cancer.
Maintaining a positive quality of life - at the time of diagnosis, during treatment and after completion of treatment – is a crucial aspect of treatment outcomes and breast cancer care
Additional information to support partners and caregivers have been provided by a variety of cancer groups.